On April 25, 2022 AI Therapeutics, Inc., an AI driven clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, reported the acquisition of EntreChem, S.L.’s investigational drug candidate EC-8042 (redesignated AIT-102), a novel targeted cancer therapy in development for rare pediatric and other cancers (Press release, EntreChem, APR 25, 2022, View Source [SID1234648560]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Despite recent advances in the understanding of tumor biology, treatment for many pediatric cancers remains limited to surgery, radiation and chemotherapy which often have poor outcomes and are associated with significant side effects. AIT-102 specifically targets the mutations responsible for the formation and progression of two notable pediatric tumors, rhabdoid tumors and Ewing sarcoma, and holds the potential to treat a broader family of tumors that share a common mechanism of mutated or dysregulated SWI/SNF activity.

"As a physician treating children with cancer on a daily basis, I am acutely aware of the need for more effective and less toxic therapies," said Patrick Grohar, M.D., Ph.D., Director of Translational Research with the Center of Childhood Cancer Research at Children’s Hospital of Philadelphia, a leader in the study and treatment of pediatric tumors. "For many tumor types, the biological culprit is well understood, but has proven difficult to target with pharmaceuticals. I have dedicated the last 15 years of my professional career to understanding the mechanism of tumor biology in children and finding new, targeted, therapies to treat these tumors. I am particularly impressed with the strong preclinical data from our studies of AIT-102 in rhabdoid tumors and Ewing sarcoma, and I believe that AIT-102 has the potential to transform the treatment of these cancers, as well as many others."

"AIT-102 is a powerful addition to AI Therapeutics’ rare disease treatment pipeline," said Brigette Roberts, M.D., Chief Executive Officer of AI Therapeutics. "Cancer is the leading cause of death by disease in children in the US today. With AIT-102, we hope to change these statistics. Beyond pediatrics, AIT-102 has the potential to treat up to 20% of cancers with altered SWI/SNF activity, either through mutation or dysregulation, including epithelioid sarcoma, synovial sarcoma, lung adenocarcinoma, colorectal cancer, and others. We are thrilled to have this opportunity to bring forward a promising new agent to help fight these tumors."

Financial terms of the transaction were not disclosed.

On 25 April 2022 Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of untapped tumour-specific antigens (TSAs), reported a $13.6M (£10.3M) seed investment from a transatlantic syndicate of top-tier life sciences investors, including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital (CIC) and Fonds de solidarité FTQ (Press release, Epitopea, APR 25, 2022, View Source [SID1234632198]). The seed round was also supported by Novateur Ventures and the Harrington Discovery Institute/University Health Holdings. The funding will leverage Epitopea’s ground-breaking CryptigenTM approach to create transformational immunotherapies that target broad cancer patient populations in both solid and haematological cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company’s proprietary technology provides an innovative approach to identifying shared, aberrantly expressed tumour specific antigens, known as CryptigensTM, that it has exclusively licensed from the Université de Montréal (UdeM). The licensing deal was catalysed by IRICoR, a Canadian Centre of Excellence in Commercialization and Research, which supported and incubated the development of the technology. CryptigenTM TSAs are uniquely and broadly presented across cancer types, providing tumour-specific targets for immunotherapies that are predicted to kill malignant cells while sparing non-cancerous cells, potentially delivering significant therapeutic benefit across broad patient populations with minimal side effects.

The seed round funding will be used to build the company’s executive team, advance further research on this new class of antigens, and catalyse their translation into novel cancer immunotherapeutics, including therapeutic vaccines, cell therapies, and TCR-based biologics.

Dr Jon Moore, CEO, Epitopea and Operating Partner at Advent Life Sciences, said

"The outstanding work of Epitopea’s co-founders, Université de Montréal scientists Drs. Claude Perreault, and Pierre Thibault, has opened a tremendous and potentially transformative opportunity for future cancer patients. With this significant seed financing by a syndicate of world-class investors from Canada and the UK, we can start translating these discoveries into novel therapeutics. We will be guided by science, deploying the best modalities available to help cancer patients achieve durable benefits."

Dr Laurence Rulleau, Partner, CTI Life Sciences, said

"CTI is delighted to co-lead the seed round of Epitopea, which is the first investment from our third fund, CTI LSF III. We are convinced that Epitopea has the potential to fundamentally change the paradigm of how cancer patients can be treated with therapeutics vaccines and other immunotherapies to significantly improve their quality of life. Epitopea will explore a variety of early and longer-term value creation strategies including partnerships with third parties as well as developing its own therapeutic modalities based on its CryptigenTM TSAs."

On April 25, 2022 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) ("BioVaxys" or "Company"), reported that it has entered into an agreement with the Deaconess Research Institute ("DRI") to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at Deaconess Health System ("Deaconess") (Press release, BioVaxys Technology, APR 25, 2022, View Source [SID1234614613]). DRI, based in Evansville, Indiana, is the clinical studies arm of Deaconess, a premier regional provider of health care services in the United States. Access to ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918, the Company’s autologous haptenized tumor cell vaccine for late-stage ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The standard of care for late-stage ovarian cancer often involves surgically debulking of the tumor mass. The debulked tumor cells will be used to test and validate the tumor collection protocol, cryopackaging, cryopreservation, and supply chain logistics for BVX-0918 bioproduction. Following shipment to BioElpida s.a. ("BioElpida"), the Company’s bioproduction partner in Lyon, France, the tumor cells will then be used for process testing and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production, a requirement for the planned Clinical Trial Application ("CTA") with the European Medicines Agency ("EMA"). BioVaxys, together with its EU partner, ProCare Health of Barcelona, Spain, is preparing to launch a Phase I clinical study for BVX-0918 later this year.

BioElpida developed various tests and validation procedures needed to support GMP manufacturing, such as sterility testing for transport, hapten fixation, and cryopreservation solutions, as well as antibody generation, bioburden screening of the haptens, and endotoxin assays; access to debulked tumor means that BioElpida will begin the final stages of the vaccine production protocol and GMP validation. BioVaxys and BioElpida have also designed and fabricated a specialized shipping package which would cryopreserve the tumor sample while in transit from any hospital site to the BioElpida site.

BioVaxys President & Chief Operating Officer Kenneth Kovan says, "Having complied with the regulatory oversight involved in obtaining waste tumor samples, BioVaxys is now able to provide BioElpida with the materials required for finalizing the vaccine production protocol and performing process validation in the lead up to our planned CTA submission to the European regulator."

BioVaxys’ vaccine platform is based on the established immunological concept that modifying surface proteins—whether they are viral or tumor—with haptens makes them more visible to the immune system. This process of haptenization "teaches" a patient’s immune system to recognize and make target proteins more "visible" as foreign, thereby stimulating a T-cell mediated immune response. BioVaxys’ cancer vaccines are created by extracting a patient’s own (autologous) cancer cells, chemically linking with a hapten, and re-injecting them into the patient to induce an immune response to proteins which are otherwise not immunogenic. Haptenization is a well-known and well-studied immunotherapeutic approach to cancer immunotherapy and has been clinically evaluated in both regional and disseminated metastatic tumors.

A first generation single-hapten vaccine invented by BioVaxys Co-Founder and Chief Medical Officer David Berd, MD, achieved positive immunological and clinical results in Phase I and Phase II human trials in over 600 patients with different tumor types, as well as having no observed toxicity in years of clinical study. These studies were conducted under an FDA-reviewed IND. A first generation autologous, haptenized vaccine was also tested by Dr. Berd in women with advanced ovarian cancer who had ceased to respond to conventional chemotherapy. The results were encouraging: In 24 patients, the median overall survival was 25.4 months with a range of 4.5-57.4 months; 8 patients survived for more than 2 years. BioVaxys has enhanced the first-generation approach by utilizing two haptens ("bi-haptenization"), which the Company believes will yield superior results.

On April 25, 2022 Shuwen Biotech, an integrated in vitro diagnostic company with focuses on women’s health, reported that it has obtained a CE mark for its quantitative qPCR kit for measuring ERBB2 gene expression in breast cancer tissue (CercaTestTM ERBB2 Assay) (Press release, Shuwen Biotech, APR 25, 2022, View Source [SID1234613090]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Immunohistochemistry (IHC) analysis of HER2 protein expression and fluorescent in situ hybridization (FISH) have been used to characterize HER2 status in breast cancer to guide anti-HER2 therapies. However, studies have shown that current standard qualitative HER2 IHC assay is insufficient especially in the low range (0 and 1+) of HER2 expression. In particular, a recent study showed the use of HER2 IHC assays as a companion diagnostic test for the new drug trastuzumab deruxtecan may result in misassignment of patients for treatment.1 In view of the direct link between gene amplification, RNA transcription, and protein expression, experts have suggested measures of messenger RNA as potentially a more reproducible quantitative assay.2

CercaTestTM ERBB2 Assay is a quantitative real-time PCR assay for accurate measurement of ERBB2 gene expression in breast cancer tissue slices. Contiguous quantitative PCR cycle numbers may be generated from different FFPE tissue samples with the same IHC scores (such as HER2 0 or 1+), allowing delineation of different ERBB2 mRNA expression levels in full spectrum. The assay is run on commonly available PCR platforms, thus obviating the need for pathology readings and scorings and avoiding human subjectivity and errors.

"With CercaTestTM ERBB2 Assay and MammaTyper, we have shown that qPCR analysis of ERBB2 mRNA in our assays exhibits high inter- and intra-laboratory reproducibility and good concordance with HER2 IHC scores by experienced pathologists, even in HER2 low expression samples.3, 4 Coupled with our RNXtract Nucleic Acid Extraction Kit and RNXtract Automated Purification System, CercaTestTM ERBB2 Assay provides simple, fast, reproducible and accurate assessment of ERBB2 mRNA levels in tissue samples including HER2-low breast cancer samples. We believe our CercaTestTM ERBB2 Assay and MammaTyper potentially offer superior companion diagnostics for anti-HER2 therapies especially the newer generation of anti-Her2 ADC drugs," commented Barclay Li, Chief Scientific Officer of Shuwen Biotech. Both CercaTestTM ERBB2 Assay and MammaTyper are commercially available worldwide through Cerca Biotech GmbH, a European subsidiary of Shuwen Biotech.

1. Fernandez et al., Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue,
JAMA Oncol. 2022 Apr 1; 8(4):1-4. doi: 10.1001/jamaoncol.2021.7239.
2. Allison et al., ERBB2-Low Breast Cancer-Is It a Fact or Fiction, and Do We Have the Right Assay? JAMA Oncol. 2022 Apr 1; 8(4):610-611. doi: 10.1001/jamaoncol.2021.7082.
3. Wirtz et al., Biological Subtyping of Early Breast Cancer: A Study Comparing RT-qPCR with Immunohistochemistry. Breast Cancer Res Treat. 2016 May 24; 157:437–446. Doi: 10.1007/s10549-016-3835-7
4. Varga et al., An International Reproducibility Study Validating Quantitative Determination of ERBB2, ESR1, PGR, and MKI67 mRNA in Breast Cancer Using MammaTyper, Breast Cancer Res. 2017 May 11; 19(1):55. doi: 10.1186/s13058-017-0848-z.

On April 25, 2022 Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a leading pan-American (ex-US) specialty pharmaceutical company, reported that Samira Sakhia, President and Chief Executive Officer, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 2, 2022 at 10:30 a.m. ET at the Metro Toronto Convention Centre in Toronto (Press release, Knight Therapeutics, APR 25, 2022, View Source [SID1234612977]). A copy of the presentation will be available at www.gud-knight.com.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!